# Peptide Vaccine Therapy in Colorectal Cancer

## TL;DR

This paper reviews the development and challenges of using peptide vaccines as a less toxic treatment for colorectal cancer.

## Contribution

The paper provides a comprehensive review of recent clinical trials and immunologic strategies in peptide vaccine therapy for colorectal cancer.

## Key findings

- Peptide vaccine therapy has shown limited success in clinical trials for colorectal cancer.
- Understanding immune system mechanisms is crucial for improving peptide vaccine effectiveness.
- Molecular targets in colon cancer are being explored to enhance vaccine therapy outcomes.

## Abstract

Colorectal cancer is the third most common cause of cancer-related deaths and the second most prevalent (after breast cancer) in the western world. High metastatic relapse rates and severe side effects associated with the adjuvant treatment have urged oncologists and clinicians to find a novel, less toxic therapeutic strategy. Considering the limited success of the past clinical trials involving peptide vaccine therapy to treat colorectal cancer, it is necessary to revise our knowledge of the immune system and its potential use in tackling cancer. This review presents the efforts of the scientific community in the development of peptide vaccine therapy for colorectal cancer. We review recent clinical trials and the strategies for immunologic monitoring of responses to peptide vaccine therapy. We also discuss the mechanisms underlying the therapy and potential molecular targets in colon cancer.